WallStSmart

Micron Technology Inc (MU)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 9% more annual revenue ($63.32B vs $58.12B). MU leads profitability with a 41.5% profit margin vs 11.8%. MU appears more attractively valued with a PEG of 0.20. MU earns a higher WallStSmart Score of 80/100 (A-).

MU

Exceptional Buy

80

out of 100

Grade: A-

Growth: 8.7Profit: 10.0Value: 6.3Quality: 8.5
Piotroski: 4/9Altman Z: 3.06

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MU.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MU6 strengths · Avg: 10.0/10
Market CapQuality
$729.23B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.2010/10

Growing faster than its price suggests

Return on EquityProfitability
39.8%10/10

Every $100 of equity generates 40 in profit

Profit MarginProfitability
41.5%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
67.6%10/10

Strong operational efficiency at 67.6%

Revenue GrowthGrowth
196.3%10/10

Revenue surging 196.3% year-over-year

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

MU2 concerns · Avg: 4.0/10
P/E RatioValuation
30.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.6x4/10

Trading at 11.6x book value

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : MU

The strongest argument for MU centers on Market Cap, PEG Ratio, Return on Equity. Profitability is solid with margins at 41.5% and operating margin at 67.6%. Revenue growth of 196.3% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : MU

The primary concerns for MU are P/E Ratio, Price/Book.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

MU profiles as a growth stock while PFE is a value play — different risk/reward profiles.

MU carries more volatility with a beta of 1.92 — expect wider price swings.

MU is growing revenue faster at 196.3% — sustainability is the question.

MU generates stronger free cash flow (6.5B), providing more financial flexibility.

Bottom Line

MU scores higher overall (80/100 vs 55/100), backed by strong 41.5% margins and 196.3% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Micron Technology Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Micron Technology, Inc. is an American producer of computer memory and computer data storage including dynamic random-access memory, flash memory, and USB flash drives. It is headquartered in Boise, Idaho.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?